SHILPAMED

March 5 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• NCLT APPROVES AMALGAMATION OF SHILPA THERAPEUTICS WITH SHILPA MEDICARE

Source text: ID:nBSEw91wt

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

Feb 24 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - BIOLOGICALS AND STEINCARES TO COMMERCIALIZE BIOSIMILAR IN LATIN AMERICA

• SHILPA MEDICARE LTD - BIOLOGICALS TO DEVELOP AND MANUFACTURE BIOSIMILAR IN INDIA

Source text: ID:nBSE1MMxp4

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;))

Feb 13 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• ENTERS AGREEMENT WITH NXI THERAPEUTICS FOR NEW CHEMICAL ENTITY

Source text: ID:nBSEDlkPS

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;))

** Shares of India's Shilpa Medicare SHME.NS up 7.2% to 339 rupees

** Co's third-qtr consol core profit rises 40% y/y, total rev up 28%

** Trading vols over 1.7 mln shares vs 30-day avg of ~502k shares

** YTD stock up over 5%

(Reporting by Hritam Mukherjee in Bengaluru)

((Hritam.Mukherjee@thomsonreuters.com;))

Feb 6 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - FILES ROTIGOTINE TRANSDERMAL PATCH ANDA TO USFDA

Source text: ID:nNSE6v2cf3

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;))

Jan 28 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• CO AND MABTREE BIOLOGICS RECEIVE FDA ORPHAN DRUG DESIGNATION

Source text: ID:nNSEsVkvf

Further company coverage: SHME.NS

((Reutersbriefs@thomsonreuters.com;))

Dec 30 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - RECEIVES INJUNCTION FROM DELHI HIGH COURT

• SHILPA MEDICARE LTD - RESTRAINED FROM MANUFACTURING AND EXPORTING RUXOLITINIB

Source text: ID:nNSE7Ggr0N

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;))

** Shares of Shilpa Medicare SHME.NS rise 3.2% to 845 rupees, their biggest intraday-pct gain in over 5 weeks

** Drug maker gets initial clearance from European drug regulator recommending final approval to sell Rivaroxaban Orodispersible Films, used to treat blood clots, heart attack, stroke in adults

** Europe market for oral Rivaroxaban formulations seen at about $2.5 billion - SHME

** Over 135,000 shares traded, over twice the 30-day avg

** Stock up 3.6% YTD

(Reporting by Aleef Jahan)

((aleefjahan.cs@thomsonreuters.com))

Aug 13 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• JUNE-QUARTER CONSOL NET PAT 468.9 MILLION RUPEES

• JUNE-QUARTER CONSOL INCOME FROM OPERATIONS 2.64 BILLION RUPEES

• RE-APPOINTMENT OF CHAIRMAN OM PRAKASH INANI

• ISSUE OF BONUS EQUITY SHARES IN RATIO OF 1:1

Source text: [ID:]

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

Aug 8 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - TO CONSIDER ISSUE OF BONUS SHARES

Source text: ID:nBSE71Gd5H

Further company coverage: SHME.NS

((reuters.briefs@thomsonreuters.com;))

July 24 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - UNIT TO INVESTS $2 MILLION IN ALVEOLUS BIO

Source text: ID:nBSE946Hpt

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Shares of Shilpa Medicare SHME.NS climb 4.5% to 932.6 rupees; set for best day in about 2 months

** Pharma co says U.S. FDA issues voluntary action indicated (VAI) classification for a Bengaluru facility

** VAI classification implies that the facility will not face any regulatory action

** YTD, stock up 14% so far

(Reporting by Manvi Pant in Bengaluru)

((Manvi.Pant@thomsonreuters.com; +918447554364;))

** Shilpa Medicare SHME.NS up 4.4% to 658.4 rupees

** Co's biologics arm Shilpa Biologics' site in Karnataka gets European Good Manufacturing Practice (GMP) certification for manufacturing of test batches

** Stock set to snap five straight sessions of losses

** SHME trims YTD losses to ~19%

(Reporting by Anuran Sadhu in Bengaluru)

((Anuran.Sadhu@thomsonreuters.com; +91 8697274436;))

April 17 (Reuters) - Celltrion Inc 068270.KS:

• ENTERING INTO A SETTLEMENT WITH CELLTRION

• SETTLEMENT FOR US$3.4 MILLION

• CO WILL PAY CELLTRION $ 3.4 MILLION, PAYABLE IN A STAGGERED MANNER TILL JULY 2025

Source text: ID:nBSE9MZBLd

Further company coverage: 068270.KS

((Reuters.Briefs@thomsonreuters.com;;))

April 9 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• US APPROVAL FOR VARENICLINE TABLETS

• RECEIVED APPROVAL FROM USFDA FOR VARENICLINE TABLETS, 0.5 AND 1 MG

Source text: ID:nBSE1NbXmT

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Shares of Shilpa Medicare SHME.NS rise 4.7% to 678.5 rupees

** Co's partner, Amneal Pharma, launched IV administered-version of its cancer drug Boruzu

** Trading volume of ~500,000 shares is 1.4x its 30-day avg

** Stock has shed 20% so far this year

(Reporting by Ashna Teresa Britto in Bengaluru)

((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))

** Shares of Shilpa Medicare SHME.NS rise 2.4% at 645 rupees

** SHME on Monday says its unit enters into deal with Switzerland-based mAbTree Biologics for development, manufacture, marketing and sale of a new biological entity

** Stock set to gain for a second session straight

** SHME shares down ~23% so far this year; pharma index .NIPHARM down ~11%

(Reporting by Yagnoseni Das in Bengaluru)

((Yagnoseni.Das@thomsonreuters.com;))

March 17 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA BIOLOGICALS ENTERED INTO A BINDING TERM SHEET WITH MABTREE BIOLOGICS AG

• TERM SHEET FOR DEVELOPMENT, MANUFACTURE, MARKETING, SALE OF NEW BIOLOGICAL ENTITY

Source text: ID:nBSEbZ3Nz0

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

March 14 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• USFDA INSPECTION AT SHILPA PHARMA UNIT-2 CLOSED WITH ZERO OBSERVATIONS

Source text: ID:nBSE3MDjcb

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

March 7 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - USFDA CONDUCTS INSPECTION AT SHILPA PHARMA UNIT-1

• SHILPA MEDICARE LTD - PHARMA RECEIVES ONE PROCEDURAL OBSERVATION FROM USFDA

Source text: ID:nBSE6XF7ph

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;))

Feb 13 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - RECEIVES CDSCO APPROVAL FOR NOR URSODEOXYCHOLIC ACID TABLETS

• SHILPA MEDICARE LTD - CDSCO RECOMMENDS MARKETING AUTHORIZATION FOR NAFLD TREATMENT

Source text: ID:nBSE1MjXx2

Further company coverage: SHME.NS

((reuters.briefs@thomsonreuters.com;))

Jan 23 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SUBSIDIARY RECEIVED CERTIFICATE OF SUITABILITY FROM EDQM FOR API, TERIFLUNOMIDE

Source text: ID:nBSE24mLds

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

Jan 10 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• GETS EUROPE APPROVAL FOR TADALAFIL ORODISPERIBLE FILMS

Source text: ID:nBSEc1X0WN

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

Dec 20 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• EUROPE GMP CERTIFICATE FOR UNIT VII, NACHARAM, HYDERABAD FROM EMA, AUSTRIA

Source text: ID:nBSE2TbwK6

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

Nov 27 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• USFDA APPROVAL OF NDA IMKELDI FILLED BY PARTNER SHORLA ONCOLOGY

Source text: ID:nBSE8whSvr

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

Nov 19 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE - UNIT RECEIVED CEP FROM EDQM FOR API, NIFEDIPINE

• SHILPA MEDICARE - GETS CERTIFICATE OF SUITABILITY FROM EUROPEAN AGENCY FOR API, NIFEDIPINE

Source text: ID:nBSE349RP4

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;))

Nov 18 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE - RECEIVED CEP FROM EDQM FOR API, OCTREOTIDE

• SHILPA MEDICARE - UNIT GOT CERTIFICATE OF SUITABILITY FROM EDQM

Further company coverage: SHME.NS

((reuters.briefs@thomsonreuters.com;))

** Shares of Shilpa Medicare SHME.NS rise 6.7% to 880 rupees, their biggest one-day gain since Oct. 8

** Pharma co's Q2 consol profit and revenue rises over 11-fold and 13%, respectively, helped by traction in its emerging markets and formulation segment

** SHME sees third-busiest day in nearly three months, with over 391,000 shares traded

** Stock extends YTD gains to 166% vs 122% gain in peer Solara Active Pharma SOLA.NS

(Reporting by Aleef Jahan in Bengaluru)

((aleefjahan.cs@thomsonreuters.com))

Nov 13 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SEPT-QUARTER CONSOL NET PAT 179.4 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 3.44 BILLION RUPEES

Source text: ID:nBSE2xtgsB

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))

Oct 31 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• CONCLUSION OF USFDA INSPECTION OF CO'S UNIT VI IN BENGALURU

• INSPECTION CONCLUDED WITH ISSUANCE OF FORM 483 WITH FOUR OBSERVATIONS

Source text: ID:nBSE2Nl2Pb

Further company coverage: SHME.NS

((Reuters.Briefs@thomsonreuters.com;;))